An example of such a marker is PSA, which, in a long-term study of 1167 men aged 60 not subject to screening16, had a much higher AUC for prostate cancer death (0.90) than for prostate cancer incidence (0.76), with the proportion of cases/deaths in the top 50%, 33%, and 10% of PSA levels being 80%/95%, 70% / 91%, and 41% / 66%, respectively. This evidence concerns the gene KLK3 and prostate carcinoma.